How Much Are Medical Innovations Worth? A Detailed Analysis Using Cost-Effectiveness Studies
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Lakdawalla, Darius & Malani, Anup & Reif, Julian, 2017.
"The insurance value of medical innovation,"
Journal of Public Economics, Elsevier, vol. 145(C), pages 94-102.
- Darius Lakdawalla & Anup Malani & Julian Reif, 2015. "The Insurance Value of Medical Innovation," NBER Working Papers 21015, National Bureau of Economic Research, Inc.
- DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
- Castanheira, Micael & Ornaghi, Carmine & Siotis, Georges, 2019.
"The unexpected consequences of generic entry,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2019. "The Unexpected Consequences of Generic Entry," ULB Institutional Repository 2013/298643, ULB -- Universite Libre de Bruxelles.
- Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
- Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
- David M. Cutler & Mark McClellan & Joseph P. Newhouse & Dahlia Remler, 1998. "Are Medical Prices Declining? Evidence from Heart Attack Treatments," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 113(4), pages 991-1024.
- Kevin M. Murphy & Robert H. Topel, 2006.
"The Value of Health and Longevity,"
Journal of Political Economy, University of Chicago Press, vol. 114(5), pages 871-904, October.
- Kevin M. Murphy & Robert H. Topel, 2005. "The Value of Health and Longevity," NBER Working Papers 11405, National Bureau of Economic Research, Inc.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018.
"Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?,"
Risks, MDPI, vol. 6(3), pages 1-27, July.
- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Post-Print hal-01571937, HAL.
- Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
- Lakdawalla, Darius N. & Phelps, Charles E., 2020. "Health technology assessment with risk aversion in health," Journal of Health Economics, Elsevier, vol. 72(C).
- Lucarelli, Claudio & Nicholson, Sean & Tilipman, Nicholas, 2022. "Price Indices and the Value of Innovation with Heterogenous Patients," Journal of Health Economics, Elsevier, vol. 84(C).
- Kuhn, Michael & Frankovic, Ivan & Wrzaczek, Stefan, 2017.
"Medical Progress, Demand for Health Care, and Economic Performance,"
VfS Annual Conference 2017 (Vienna): Alternative Structures for Money and Banking
168249, Verein für Socialpolitik / German Economic Association.
- Frankovic, Ivan & Kuhn, Michael & Wrzaczek, Stefan, 2017. "Medical progress, demand for health care, and economic performance," ECON WPS - Working Papers in Economic Theory and Policy 08/2017, TU Wien, Institute of Statistics and Mathematical Methods in Economics, Economics Research Unit.
- Dosis, Anastasios & Muthoo, Abhinay, 2019.
"Experimentation in Dynamic R&D Competition,"
CRETA Online Discussion Paper Series
52, Centre for Research in Economic Theory and its Applications CRETA.
- Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," The Warwick Economics Research Paper Series (TWERPS) 1214, University of Warwick, Department of Economics.
- Anastasios, Dosis & Abhinay, Muthoo, 2019. "Experimentation in Dynamic R&D Competition," ESSEC Working Papers WP1901, ESSEC Research Center, ESSEC Business School.
- Anastasios Dosis & Abhinay Muthoo, 2019. "Experimentation in Dynamic R&D Competition," Working Papers hal-02102518, HAL.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
- Bae, Joonhyung & Ozmel, Umit, 2024. "The interplay between product development failures and alliance portfolio properties in the formation of exploration versus exploitation alliances," Journal of Business Research, Elsevier, vol. 177(C).
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
NBER Working Papers
30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Frankovic, Ivan & Kuhn, Michael, 2023. "Health insurance, endogenous medical progress, health expenditure growth, and welfare," Journal of Health Economics, Elsevier, vol. 87(C).
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
- Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
- Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011.
"The Pragmatist's Guide to Comparative Effectiveness Research,"
Journal of Economic Perspectives, American Economic Association, vol. 25(2), pages 27-46, Spring.
- Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," NBER Working Papers 16990, National Bureau of Economic Research, Inc.
- Karen Eggleston & Brian K. Chen & Chih-Hung Chen & Ying Isabel Chen & Talitha Feenstra & Toshiaki Iizuka & Janet Tin Kei Lam & Gabriel M. Leung & Jui-fen Rachel Lu & Beatriz Rodriguez-Sanchez & Jeroen, 2020.
"Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 689-702, July.
- Karen Eggleston & Brian K. Chen & Chih-Hung Chen & Ying Isabel Chen & Talitha Feenstra & Toshiaki Iizuka & Janet Tinkei Lam & Gabriel M. Leung & Jui-fen Rachel Lu & Beatriz Rodriguez-Sanchez & Jeroen , 2019. "Are Quality-Adjusted Medical Prices Declining for Chronic Disease? Evidence from Diabetes Care in Four Health Systems," NBER Working Papers 25971, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- E31 - Macroeconomics and Monetary Economics - - Prices, Business Fluctuations, and Cycles - - - Price Level; Inflation; Deflation
- O30 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - General
- I10 - Health, Education, and Welfare - - Health - - - General
NEP fields
This paper has been announced in the following NEP Reports:- NEP-HEA-2024-12-30 (Health Economics)
- NEP-INO-2024-12-30 (Innovation)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bea:papers:0132. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Andrea Batch (email available below). General contact details of provider: https://edirc.repec.org/data/beagvus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.